Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;11(2):151–168. doi: 10.1111/j.1527-3458.2005.tb00267.x

Mildronate: An Antiischemic Drug for Neurological Indications

Nikolajs Sjakste 1,2,✉, Aleksandrs Gutcaits 2, Ivars Kalvinsh 2
PMCID: PMC6741751  PMID: 16007237

ABSTRACT

Mildronate (3‐(2,2,2‐trimethylhydrazinium)propionate; MET‐88; meldonium, quaterine) is an antiischemic drug developed at the Latvian Institute of Organic Synthesis. Mildronate was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid β‐oxidation in ischemic tissues and to block this highly oxygen‐consuming process. Mildronate is efficient in the treatment of heart ischemia and its consequences. Extensive evaluation of pharmacological activities of mildronate revealed its beneficial effect on cerebral circulation disorders and central nervous system (CNS) functions. The drug is used in neurological clinics for the treatment of brain circulation disorders. It appears to improve patients' mood; they become more active, their motor dysfunction decreases, and asthenia, dizziness and nausea become less pronounced. Since the brain does not utilize fatty acids as fuel other mechanisms of action of mildronate in CNS should be considered. Several reports indicate the possible existence of an alternative, non‐carnitine dependent mechanism of action of mildronate. Our recent findings suggest that CNS effects of mildronate could be mediated by stimulation of the nitric oxide production in the vascular endothelium by modification of the γ‐butyrobetaine and its esters pools. It is hypothesized that mildronate may increase the formation of the γ‐butyrobetaine esters. The latter are potent cholinomimetics and may activate eNOS via acetylcholine receptors or specific γ‐butyrobetaine ester receptors. This article summarizes known pharmacological effects of mildronate, its pharmacokinetics, toxicology, as well as the proposed mechanisms of action.

Keywords: Antiischemic drugs, Cerebral circulation, γ‐Butyrobetaine hydroxylase inhibitors, Mildronate, Nitric oxide

Full Text

The Full Text of this article is available as a PDF (156.4 KB).

REFERENCES

  • 1. Abeuov BA, Raimkulov BN, Mitrokhin DA, et al. Condition of the higher brain functions in patients with dyscirculatory encephalopathy treated with mildronate. Meditsina 2004;2:78–81 (in Russian). [Google Scholar]
  • 2. Beketov AI, Mametova AN, Polevik IV, Sapegin ID. Comparative characteristics of cerebrovascular protective effects of mildronate, riboxine, and their combination during modeling of cerebral hemodynamics disturbance. Éksp Klin Farmakol 2000;63:18–21 (in Russian). [PubMed] [Google Scholar]
  • 3. Belitskii GA, Kalvinysh, IIa , Anisimov, VN , Khovanova EM, Ugvinenko EG, Tolcheev, IuD. Absence of mutagenic and carcinogenic properties in mildronate. Vopr Onkol 1999;45:279–282 (in Russian). [PubMed] [Google Scholar]
  • 4. Blium, IaB , Babeniuk, Yu D , Kalvin'sh, IIa , Bratus, NI , Kucherenko NE. Influence of the Mildronate on intensity of the ADP‐ribosylation of chromatin proteins. Latv Zinatnu Akad Vestis 1990;8:120–125 (in Russian). [Google Scholar]
  • 5. Blium, Ia. B , Kalvin'sh, IIa , Kucherenko, NE , Lukevits, EIa. Effect of quaterin and S‐methylmethionine on the intensity of chromatin protein methylation. Voen-Med Zh 1987;59:18–24 (in Russian). [PubMed] [Google Scholar]
  • 6. Blium, IaB , Kalvin, 'Shiia , Kucherenko, NE , Lukevits, EIa. Stimulation with quaterin of DNA replication and repair. Voen-Med Zh 1988;60:19–23 (in Russian). [PubMed] [Google Scholar]
  • 7. Blium, IaB , Verbovikova, EA , Kalvin'sh, IIa , Bratus, NI , Babeniuk, YuD , Kucherenko, NE. Influence of the trimethylhydrazine analogue of gamma‐butyrobetaine — Mildronate — on the pre‐mRNA biosynthesis. Latv Zinatnu Akad Vestis 1990;10:105–109 (in Russian). [Google Scholar]
  • 8. Chiba S, Akahane K, Furukawa Y, Karasawa Y. Direct chronotropic and inotropic effects of mildronate using cross‐circulated dog atrial and ventricular preparations. Jpn Heart J 1989;30:743–750. [DOI] [PubMed] [Google Scholar]
  • 9. Dambrova M, Chlopicki S, Liepinsh E, et al. The methylester of gamma‐butyrobetaine, but not gamma‐butyrobetaine itself, induces muscarinic receptor‐dependent vasodilatation. Naunyn Schmiedeberg's Arch Pharmacol 2004;369:533–539. [DOI] [PubMed] [Google Scholar]
  • 10. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: Cardioprotective action through carnitine‐lowering effect. Trends Cardiovasc Med 2002;12:275–279. [DOI] [PubMed] [Google Scholar]
  • 11. Degrace P, Demizieux L, Gresti J, et al. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Mol Cell Biochem 2004;258:171–182. [DOI] [PubMed] [Google Scholar]
  • 12. Dziak LA, Golik VA. Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head. Lik Sprava 2003;5–6:98–101 (in Russian). [PubMed] [Google Scholar]
  • 13. Dzintare M. Changes of concentration of nitric oxide in tissues under action of different pharmacological agents Summary of a Doctoral. Thesis Riga : University of Latvia, 2004;1–76. [Google Scholar]
  • 14. Dzintare M, Baumane L, Meirena D, Lauberte L, Kalvinsh I, Sjakste N. Involvement of nitric oxide production in the mildronate mechanism of action. Pharmacol Rev Commun 2002;12:163–170. [Google Scholar]
  • 15. Enina G, Timofeeva T, Egere D, Majore I. Medicinal effects and indications to mildronate application in neuroangiologic practice. Éksp Klin Farmakoter (Riga) 1991;Issue 19:164–171 (in Russian). [Google Scholar]
  • 16. Frantsuzova SB., Jatsetnko VP, Zotov AS, Antonenko LI, Arshinnikova LL. Pharmacodynamics of mildronate: A review. Zh Akad Med Nauk Ukr 1997;3:612–624 (in Russian). [Google Scholar]
  • 17. Gaidar BV, Parfenov VE, Vainshtein GB. Ways to optimize the cerebral circulation during extreme actions on the brain. Fiziol Zh Sechenova 1989;75:1568–1575 (in Russian). [PubMed] [Google Scholar]
  • 18. Galland S, Le Borgne, F , Guyonnet D, Clouet P, Demarquoy J. Purification and characterization of the rat liver gamma‐butyrobetaine hydroxylase. Mol Cell Biochem 1998;178:163–168. [DOI] [PubMed] [Google Scholar]
  • 19. Georges B, Le Borgne, F , Galland S, et al. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Biochem Pharmacol 2000;59:1357–1363. [DOI] [PubMed] [Google Scholar]
  • 20. Germane S. Experimental study of mildronate effect on the central nervous system. Éksp Klin Farmakoter (Riga) 1991;Issue 19:44–50 (in Russian). [Google Scholar]
  • 21. Germane S., Berzina D. Effect of mildronate on catecholamine level and somatic manifestations in white rats organs under stress. Éksp Klin Farmakoter (Riga) 1991;Issue 19:51–56 (in Russian). [Google Scholar]
  • 22. Hayashi Y, Ishida H, Hoshiai M, et al. MET‐88, a gamma‐butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction. Mol Cell Biochem 2000;209:39–46. [DOI] [PubMed] [Google Scholar]
  • 23. Hayashi Y, Muranaka Y, Kirimoto T, Asaka N, Miyake H, Matsuura N. Effects of MET‐88, a gamma‐butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol Pharm Bull 2000;236:770–773. [DOI] [PubMed] [Google Scholar]
  • 24. Heidemanis K, Balcere I, Kalvinsh I. Mildronate‐plasma membrane interaction mechanisms. Latv Zinatnu Akad Vestis 1990;11:108–115. [Google Scholar]
  • 25. Herrera MD, Bueno R, de Sotomayor MA, Perez‐Guerrero C, Vazquez CM, Marhuenda E. Endothelium‐dependent vasorelaxation induced by L‐carnitine in isolated aorta from normotensive and hypertensive rats. J Pharm Pharmacol 2002;54:1423–1427. [DOI] [PubMed] [Google Scholar]
  • 26. Hosein EA, Kato A, Vine E, Hill AM. The identification of acetyl‐L‐carnitylcholine in rat brain extracts and the comparison of its cholinomimetic properties with acetylcholine. Can J Physiol Pharmacol 1970;48:709–722. [DOI] [PubMed] [Google Scholar]
  • 27. Hosein EA, Proulx P. Acetylcholine‐like activity in subcellular particles isolated from rat brain. Arch Biochem Biophys 1964;106:267–274. [DOI] [PubMed] [Google Scholar]
  • 28. Hwang YC, Bakr S, Ramasamy R, Bergmann SR. Relative importance of enhanced glucose uptake versus attenuation of long‐chain acyl carnitines in protecting ischemic myocardium. Coronary Artery Dis 2002;136:313–318. [DOI] [PubMed] [Google Scholar]
  • 29. Kagan TI, Simkhovich BZ, Kalvinysh, IIa , Lukevits, EIa. Study of the effect of an inhibitor of carnitine‐dependent metabolism of mildronate on the oxidation of fatty acids in the liver mitochondria of intact rats. Vopr Med Khimii 1991;37:44–46 (in Russian). [PubMed] [Google Scholar]
  • 30. Kalvinsh I. Synthesis and pharmacological activity of a new bioregulator mildronate. Éksp Klin Farmakoter (Riga) 1991;Issue 19:7–14 (in Russian). [Google Scholar]
  • 31. Kalvinsh I, Veveris M. Pharmaceutical composition for treating cardiovascular diseases containing 3‐(2,2,2‐trimethylhydrazinium) propionate and gamma‐butyrobetaine. US Pat. 5,859,056, Int. Cl.6 A61K3/205, 01/12/1999.
  • 32. Karpov RS, Dudko VA, Shipulin VM, et al. The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries. Ter Arkh 1991;634:90–93 (in Russian). [PubMed] [Google Scholar]
  • 33. Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K, Miyake H. Beneficial effect of MET‐88, a gamma‐butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther 1996;331:163–178. [PubMed] [Google Scholar]
  • 34. Klimkane L, Koronova, Zh , Kalvinsh, I , Zakenfelds G. The effect of mildronate on cancerogenesis and on the growth of transplanted tumours. Proc Latv Acad Sci B 1992;2:54–59 (in Latvian). [Google Scholar]
  • 35. Kuwajima M, Harashima H, Hayashi M, et al. Pharmacokinetic analysis of the cardioprotective effect of 3‐(2,2,2‐trimethylhydrazinium) propionate in mice: Inhibition of carnitine transport in kidney. J Pharmacol Exp Ther 1999;289:93–102. [PubMed] [Google Scholar]
  • 36. Lerch R, Tamm C, Papageorgiou I, Benzi RH. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol Cell Biochem 1992;116:103–109. [DOI] [PubMed] [Google Scholar]
  • 37. Logai IM, Guseva OG, Kalvin'sh, IIa. The use of lysosomotropic preparations in treating severe experimental chemical eye burns. Oftal'mol Zh 1989;8:497–500 (in Russian). [PubMed] [Google Scholar]
  • 38. Lychkova AE, Savchuk VI, Smirnov VM. Experimental gastric ulcer: Gastro‐ and duodenoprotective effects of sibusol. Bull Exp Biol Med 2004;137:34–36. [DOI] [PubMed] [Google Scholar]
  • 39. Logunova LV, Sutulov, YuI. Studies on mildronate effect on the development and healing of stress ulcer stomach injuries in the experiment. Éksp Klin Farmakoter (Riga) 1992;Issue 20:82–91 (in Russian). [Google Scholar]
  • 40. Meerson FZ, Abdikaliev NA, Kalvin'sh, IIa , Vovk, VI. Bioelectrical mechanism of the anti‐arrhythmia effect of a synthetic acetylcholine analogue EDIHYP. Kardiologiya 1995;31:52–55 (in Russian). [PubMed] [Google Scholar]
  • 41. Moskalenko YE, Gaidar BV, Parfenov VE. Strategy for pharmacological correction of cerebral ischemia: Systemic approaches In: Kriegslein J, Oberpichler‐Schwenk H, Eds. Pharmacolgy of cerebral ischemia. Stuttgart : Wissenschaftliche Verlagsgesselschaft mbH, 1999. [Google Scholar]
  • 42. Okunevich IV, Ryzhenkov VE. Anti‐atherosclerotic action of mildronate in experiment. Patol Fiziol Éksp Ter 2002;2:24–27 (in Russian). [PubMed] [Google Scholar]
  • 43. Orbidane O, Meirena D, Pugovics O, et al. Gamma‐butyrobetaine esterase activity in rat blood serum. Proc Latv Acad Sci B 2004;58:98–102. [Google Scholar]
  • 44. Pcheliakov VF, Arnautova LV. Reparative post‐traumatic regeneration of the rabbit cornea after administration of quaterin. Oftal'mol Zh 1987;6:369–373 (in Russian). [PubMed] [Google Scholar]
  • 45. Petersone I, Veveris M, Berzina D, Kalnciema V, Lepika V, Eglite I. Acute and chronic toxicity of mildronate. Éksp Klin Farmakoter (Riga) 1991;Issue 19:67–71 (in Russian). [Google Scholar]
  • 46. Ratunova TM, Bauman VR, Kalvin'sh, IIa. The cardioprotective action of carnitine and its structural analog 3‐(2,2,2‐trimethylhydrazine)propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats. Farmakol Toksikol 1989;52:24–27 (in Russian). [PubMed] [Google Scholar]
  • 47. Rugaja Z, Kagan T, Majore A, et al. Effects of mildronate on experimental hepatic carcinogenesis. Latv Zinatnu Akad Vestis 1990;6:122–129 (in Russian). [Google Scholar]
  • 48. Rupp H, Zarain‐Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;27:621–636. [DOI] [PubMed] [Google Scholar]
  • 49. Salnikov SN. Cytoprotector mildronate and cerebral oxygenation. Appendix for the Information edition of the Grindex for physicians pharmaceutists and specialists, Vol. 3 Riga : 2002. ;2–4. [Google Scholar]
  • 50. Shutenko, ZhV , Meirena, DV , Kagan TI, Sjakste NI, Kalvin'sh, IIa Mildronate: Mechanisms of action, perspective for pathology correction. Khim-Pharm Zh 1995;29:13–17 (in Russian). [Google Scholar]
  • 51. Shutenko, Zh V , Priedena IA, Mezhapuke, RIa , Simkhovich, BZ , Kalvin'sh, IIa , Lukevits, EIa. The effect of the carnitine biosynthesis inhibitor mildronate on the lipid metabolic indices of rats. Farmakol Toksikol 1991;542:55–56 (in Russian). [PubMed] [Google Scholar]
  • 52. Shutenko, Zh V , Simkhovich BZ, Meirena DV, Kalvin'sh, IIa , Lukevits, EIa. Regulation of carnitine‐dependent metabolism of fatty acids in the rat myocardium using 3‐(2,2,2‐trimethylhydrazinium) propionate. Vopr Med Khimii 1989;352:59–64 (in Russian). [PubMed] [Google Scholar]
  • 53. Simkhovich BZ. Mildronate. Cardioprotector. A remedy increasing work efficiency. Riga : Academy of Sciences of the Latvian SSSR, 1988:1–4 (in Russian). [Google Scholar]
  • 54. Simkhovich BZ, Meirena DV, Khagi, KhB , Kalvin'sh IIa, Lukevits EIa. Effect of a new structural analog of gamma‐butyrobetaine‐3‐(2,2,2‐trimethylhydrazine)propionate (THP) on carnitine level, carnitine‐dependent fatty acid oxidation and various indices of energy metabolism in the myocardium. Vopr Med Khimii 1986;324:72–76 (in Russian). [PubMed] [Google Scholar]
  • 55. Simkhovich BZ, Meirena DV, Khagi, KhB , Kalvin'sh, IIa , Lukevits, EIa. Biochemical characteristics of the anti‐ischemic action of the new structural analog of gamma‐butyrobetaine 3‐(2,2,2‐trimethylhydrazine)propionate. Farmakol Toksikol 1987;50:100–104 (in Russian). [PubMed] [Google Scholar]
  • 56. Simkhovich BZ, Shutenko ZV, Meirena DV, et al. 3‐(2,2,2‐Trimethylhydrazinium) propionate (THP) — a novel gamma‐butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988;37:195–202. [DOI] [PubMed] [Google Scholar]
  • 57. Simkhovich BZ, Vitolinia RO, Stivrinia MI, Shutenko, ZhV , Meirena, DV. Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level. Kardiologiya 1987;27:85–88 (in Russian). [PubMed] [Google Scholar]
  • 58. Sizova EN, Tsirkin VI, Dvorianskii SA. The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow. Ross Fiziol Zh Sechenova 2002;88:856–864 (in Russian). [PubMed] [Google Scholar]
  • 59. Sjakste N, Baumane L, Boucher JL, et al. Effects of gamma‐butyrobetaine and mildronate on nitric oxide production in lipopolysaccharide‐treated rats. Basic Clin Pharmacol Toxicol 2004;94:46–50. [PubMed] [Google Scholar]
  • 60. Sjakste N, Kleschyov AL, Boucher JL, et al. Endothelium‐ and nitric oxide‐dependent vasorelaxing activities of gamma‐butyrobetaine esters: Possible link to the antiischemic activities of mildronate. Eur J Pharmacol 2004;495:67–73. [DOI] [PubMed] [Google Scholar]
  • 61. Sjakste N, Meirena D, Dzene A, Meapuíe R, Ignatovich L, Lukevics E. Modifications of the genome expression by several novel drugs. Exp Biol (Vilnius) 1992;26:3–4. [Google Scholar]
  • 62. Spaniol M, Brooks H, Auer L, et al. Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 2001;268:1876–1887. [PubMed] [Google Scholar]
  • 63. Suslina ZA, Fedorova TN, Maksimova, MIu , Kim, EK. Antioxidant activity of mildronate and L‐carnitine in the treatment of patients with cerebrovascular diseases. Éksp Klin Farmakol 2003;66:32–35 (in Russian). [PubMed] [Google Scholar]
  • 64. Thomizek WD, Strack E, Lorenz J. Über den Einfluß einiger Derivate aliphatischen Trimethylbetaine auf die Acetylcholine‐esterase und über die Hydrolyse von Betainestern. Acta Biol Med Germ 1963;11:353–355 (in German). [PubMed] [Google Scholar]
  • 65. Tsoko M, Beauseigneur F, Gresti J, Demarquoy J, Clouet P. Hypolipidaemic effects of fenofibrate are not altered by mildronate‐mediated normalization of carnitine concentration in rat liver. Biochimie 1998;80:943–948. [DOI] [PubMed] [Google Scholar]
  • 66. Tsoko M, Beauseigneur F, Gresti J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L‐carnitine by D‐carnitine and a gamma‐butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995;49:1403–1410. [DOI] [PubMed] [Google Scholar]
  • 67. Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J 2002;361:417–429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Vetra A, Shefere M, Skarda I, Matveja L, Kalvinsh I. Significance of mildronate for improvement of results of early rehabilitation results of neurological patients. Latvijas Arstu Zurnals 1999;12:33–37 (in Latvian). [Google Scholar]
  • 69. Vinichuk SM. The efficacy of the mildronate treatment of patients with ischemic stroke. Vrach Delo 1991;7:77–79 (in Russian). [PubMed] [Google Scholar]
  • 70. Yonekura K, Eto Y, Yokoyama I, et al. Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+‐ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol 2000;95:343–348. [DOI] [PubMed] [Google Scholar]
  • 71. Yoshisue K, Yamamoto Y, Yoshida K, et al. Pharmacokinetics and biological fate of 3‐(2,2,2‐trimethylhydrazinium)propionate dihydrate (MET‐88), a novel cardioprotective agent, in rats. Drug Metab Dispos 2000;28:687–694. [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES